Tumor cell proliferation and survival in patients with prostate cancer followed expectantly

被引:37
作者
Borre, M [1 ]
Bentzen, SM
Nerstrom, B
Overgaard, J
机构
[1] Aarhus Univ Hosp, Dept Expt Clin Oncol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Urol, DK-8000 Aarhus C, Denmark
[3] Danish Canc Soc, Aarhus C, Denmark
关键词
prostatic neoplasms; antibodies; tumor markers; biological;
D O I
10.1097/00005392-199805000-00054
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Prostate cancers have different biological potentials, and aggressive tumors are difficult to identify when still localized. Tumor cell proliferation determined by MIB-1 expression has been suggested as an important predictor for outcome in several human cancers including the prostate. We test the possible prognostic value of tumor cellular proliferation in prostate cancer patients treated with no intent to cure. Materials and Methods: Formalin fixed, paraffin embedded tumor tissue obtained at the time of diagnosis from 221 patients originating from a well known complete Danish prostate cancer population was immunohistochemically investigated. The tumor cell proliferation rate was determined using the MIB-1 antibody. Tumors were clinically localized in 57% of the patients. Results: Tumor cell proliferation rate expressed by the MIB-1 score significantly correlated with tumor stage (p < 0.001) and malignancy grade (p < 0.001). The MIB-1 score, divided into low and high by the median value, showed significant association with disease specific survival in the entire study population (p < 0.0001), as well as in the 125 patients suffering from clinically localized disease (p = 0.018). Multivariate analyses showed that MIB-1 was a significant (p = 0.0003) prognostic factor in the entire population, including advanced disease stages. However, in the theoretically curable clinically localized subpopulation MIB-1 was not significant (p = 0.08) contrary to histopathological grade (p = 0.02), erythrocyte sedimentation rate (p = 0.02) and T classification (p = 0.035). Conclusions: Prostate tumor cell proliferation, expressed by MIB-1 immunoreactivity, demonstrated significant association with disease specific survival. However, MIB-1 is a close alternative to histopathological grade in describing the natural history of clinically localized prostate cancer. The additional prognostic value and the practical consequence of tumor cell proliferation remain to be clarified.
引用
收藏
页码:1609 / 1614
页数:6
相关论文
共 41 条
  • [1] DANGERS OF USING OPTIMAL CUTPOINTS IN THE EVALUATION OF PROGNOSTIC FACTORS
    ALTMAN, DG
    LAUSEN, B
    SAUERBREI, W
    SCHUMACHER, M
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) : 829 - 835
  • [2] LONG-TERM SURVIVAL AND MORTALITY IN PROSTATE-CANCER TREATED WITH NONCURATIVE INTENT
    AUS, G
    HUGOSSON, J
    NORLEN, L
    [J]. JOURNAL OF UROLOGY, 1995, 154 (02) : 460 - 465
  • [3] TUMOR PROLIFERATION ASSESSED BY COMBINED HISTOLOGICAL AND FLOW CYTOMETRIC ANALYSIS - IMPLICATIONS FOR THERAPY IN SQUAMOUS-CELL CARCINOMA IN THE HEAD AND NECK
    BENNETT, MH
    WILSON, GD
    DISCHE, S
    SAUNDERS, MI
    MARTINDALE, CA
    ROBINSON, BM
    OHALLORAN, AE
    LESLIE, MD
    LAING, JHE
    [J]. BRITISH JOURNAL OF CANCER, 1992, 65 (06) : 870 - 878
  • [4] Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy
    Bettencourt, MC
    Bauer, JJ
    Sesterhenn, IA
    Mostofi, FK
    McLeod, DG
    Moul, JW
    [J]. JOURNAL OF UROLOGY, 1996, 156 (03) : 1064 - 1068
  • [5] RELATION OF ENDOCRINE-PARACRINE CELLS TO CELL-PROLIFERATION IN NORMAL, HYPERPLASTIC, AND NEOPLASTIC HUMAN PROSTATE
    BONKHOFF, H
    WERNERT, N
    DHOM, G
    REMBERGER, K
    [J]. PROSTATE, 1991, 19 (02) : 91 - 98
  • [6] The dilemma of prostate cancer - A growing human and economic burden irrespective of treatment strategies
    Borre, M
    Nerstrom, B
    Overgaard, J
    [J]. ACTA ONCOLOGICA, 1997, 36 (07) : 681 - 687
  • [7] Erythrocyte sedimentation rate - A predictor of malignant potential in early prostate cancer
    Borre, M
    Nerstrom, B
    Overgaard, J
    [J]. ACTA ONCOLOGICA, 1997, 36 (07) : 689 - 694
  • [8] Borre M, 1997, CANCER, V80, P917
  • [9] BORRE M, IN PRESS APMIS
  • [10] Brown C, 1996, MODERN PATHOL, V9, P205